The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins. Anthrax preparedness remains one of BARDA's top priorities. This contract builds on HHS investments in antibiotics, antitoxins, and vaccine development for anthrax...
More...
More...